Skip to main content

Published locations for Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis

User login

  • Reset your password
  • /content/upadacitinib-doubles-asas-40-response-vs-placebo-ankylosing-spondylitis
  • /internalmedicinenews/article/213422/ankylosing-spondylitis/upadacitinib-doubles-asas-40-response-vs
  • /rheumatologynews/article/213422/ankylosing-spondylitis/upadacitinib-doubles-asas-40-response-vs
  • /rheumatology/article/213422/ankylosing-spondylitis/upadacitinib-doubles-asas-40-response-vs-placebo
  • /internalmedicine/article/213422/ankylosing-spondylitis/upadacitinib-doubles-asas-40-response-vs